We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: May 21, 2012
Last Update Posted: February 11, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

This is a prospective cross-sectional, observational, single-center study of Alport patients, in which a single, first morning voided urine collection will be acquired and used to validate assays of urine biomarkers that reflect changes in glomerular protein filtration barrier function.

The purpose of this study is to identify biomarkers indicative of changes in glomerular filtration function that occur during the course of proteinuric renal diseases such as Alport nephropathy.

Alport Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Biospecimen Retention:   None Retained

Enrollment: 80
Study Start Date: September 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with Alport syndrome identified by the Alport Syndrome Treatments and Outcome Registry (ASTOR)

Inclusion criteria:

  • Alport syndrome diagnosis (clinical and/or histopathologic and/or genetic diagnosis, per subject's physician and/or genotyping)
  • Physically able to provide a single first-morning urine sample of at least 30 mL

Exclusion criteria:

  • Diagnosis of chronic kidney disease
  • Receiving chronic phosphate-lowering therapy or erythropoietin therapy
  • Ongoing chronic hemodialysis therapy and/or renal transplant recipient
  • Nephrotic-range proteinuria: spot urine protein-to-creatinine ratio ≥ 3 on at least 2 of the last 3 clinical assessments Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01602835     History of Changes
Other Study ID Numbers: CPLATFRM2201
First Submitted: May 17, 2012
First Posted: May 21, 2012
Last Update Posted: February 11, 2014
Last Verified: February 2014

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Alport syndrome
glomerular disease
hereditary nephropathy

Additional relevant MeSH terms:
Kidney Diseases
Nephritis, Hereditary
Urologic Diseases
Urogenital Abnormalities
Congenital Abnormalities
Collagen Diseases
Connective Tissue Diseases